Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China-Reference-Cited by-同舟云学术

Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China

Published:2024-05-02 Issue:1 Volume:56 Page:
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Gu Pengcheng¹,Lu Peng²,Ding Hui²,Liu Qiao²,Ding Xiaoyan²,Chen Yongfa¹,Zhu Limei²

Affiliation:

1. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

2. Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, China

Funder

Key Scientific Research Project of Health Commission of Jiangsu Province

Jiangsu Provincial Medical Key Discipline

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2024.2344821

Reference30 articles.

1. WHO. Global tuberculosis report 2022. Geneva: WHO; 2022.

2. Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis

3. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China

4. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

5. World Health Organization. WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis. 2018 update. Geneva: World Health Organization; 2018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global, regional, and national burden of HIV-negative tuberculosis, 1990–2021: findings from the Global Burden of Disease Study 2021;Infectious Diseases of Poverty;2024-08-19